McMaster University, Hamilton, ON, Canada.
Illumina Inc, San Diego, CA, USA.
J Virol Methods. 2019 May;267:48-52. doi: 10.1016/j.jviromet.2019.02.007. Epub 2019 Feb 21.
Because of its non-invasive nature urine testing may enable increased screening for HPV in women who avoid cervical sampling. Comparisons have shown fewer HPV positives in urine. The objectives were to compare first-void urine (FVU) treated with proteinase K (PK) to untreated FVU and cervical samples collected from women attending a colposcopy clinic using an Aptima HPV mRNA assay, and comparing the HPV rates to cytology and pathology results. Female FVU (n = 433) was treated with Aptima Transfer Solution (ATS) containing PK within 24 h or after months of storage. Untreated female FVU samples were HPV-positive in 20.8-27.6% compared to 34.4-45.6% of ATS-treated FVU and 44.9-48.4% of PreservCyt samples. Good overall agreement for HR-HPV detection between ATS-FVU and PreservCyt was observed (81.1%; k 0.63). Validation of ATS treatment was performed on 356 male FVU, detecting 6.7% HPV positive compared to 3.4% of untreated samples (p = 0.059). Although HPV presence in ATS FVU and PreservCyt samples were similar, significantly more women with abnormal cervical cytology and histopathology were HPV-positive in cervical specimens than in ATS-treated FVU.
由于尿液检测具有非侵入性，因此可能会增加对避免宫颈采样的女性进行 HPV 筛查的机会。已有研究表明尿液中的 HPV 阳性率较低。本研究的目的是比较经蛋白酶 K（PK）处理的首段尿液（FVU）与未经处理的 FVU 以及从接受阴道镜检查的女性收集的宫颈样本，使用 Aptima HPV mRNA 检测方法进行比较，并将 HPV 率与细胞学和病理学结果进行比较。女性 FVU（n=433）在 24 小时内或储存数月后用含有 PK 的 Aptima 转移溶液（ATS）处理。未经处理的女性 FVU 样本中 HPV 阳性率为 20.8-27.6%，而 ATS 处理的 FVU 和 PreservCyt 样本中 HPV 阳性率为 34.4-45.6%和 44.9-48.4%。ATS-FVU 和 PreservCyt 对 HR-HPV 的检测具有良好的总体一致性（81.1%；k 值为 0.63）。对 356 例男性 FVU 进行了 ATS 处理验证，检测到 6.7%的 HPV 阳性，而未经处理的样本中 HPV 阳性率为 3.4%（p=0.059）。尽管 ATS FVU 和 PreservCyt 样本中的 HPV 存在情况相似，但宫颈标本中异常宫颈细胞学和组织病理学的女性中 HPV 阳性的比例明显高于 ATS 处理的 FVU。
